- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 215 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 315 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,465 | -0,60 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen | |
| IMMATICS | 4,828 | +0,54 % | Mizuho reiterates Outperform rating on Immatics stock following Q2 results | ||
| ALDEYRA | 4,759 | -1,43 % | FDA grants fast track designation for Aldeyra's eye disease drug | ||
| MEDIFAST | 11,220 | -4,35 % | Medifast Bolsters Growth Through Health & Wellness Solutions | ||
| PHARMING | 1,059 | +0,86 % | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
20.08.2025 / 16:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,939 | +2,74 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 12,400 | -4,62 % | Oruka Therapeutics: Clear Street startet Coverage mit Kaufempfehlung wegen Psoriasis-Pipeline | ||
| DBV TECHNOLOGIES | 1,712 | -0,47 % | DBV Technologies S.A.: Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 | Information
regarding
the
total
number
of
voting
rights
and total number of shares of the Company as of July 31, 2025
(Article 223-16 of the General Regulations... ► Artikel lesen | |
| INNOVIVA | 17,600 | +2,92 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,080 | -2,80 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update | Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02
... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 1,050 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,775 | 0,00 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 13,200 | -2,22 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August... ► Artikel lesen | |
| LIQUIDIA | 23,320 | -0,60 % | Jefferies initiates Liquidia stock with Buy rating, $43 price target | ||
| MATINAS BIOPHARMA | 1,770 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
MOLECURE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,818 Euro und damit +1,22 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.